


18 January 2023 EMA/836371/2022 Stakeholders and Communication Division

Draft Agenda - PCWP/HCPWP joint meeting

3 March 2023, 09:30hrs to 16:40hrs - meeting room: 2A

Co-Chairs: Juan Garcia-Burgos (EMA), Marko Korenjak (PCWP), Rosa Giuliani (HCPWP)

Time	Topics	Speaker		
09:15	Registration and reimbursement arrangements			
09:30	Welcome and introduction / Health and safety information	Juan Garcia Burgos (EMA)		
	Disclosure of interests / Adoption of the agenda	Marko Korenjak (PCWP)		
		Rosa Giuliani (HCPWP)		
1. EMA Working parties				
09:45	Reorganisation of EMA working parties	Silvy da Rocha (EMA)		
10:00	Focus on:			
	1. SAWP – interaction with other WPs	Iordanis Gravanis (EMA)		
	2. Methodology Working Party (MWP)	Andrew Thomson (EMA)		
	3. 3Rs Working Party	Stefano Ponzano (EMA)		
10:30	Q&A			
	Discussion point: what is the interest to and how can patients and HCPs be involved in the WPs work?			
11:00	Coffee break			
2. Committee feedback				
11:15	6 ppt (10' each)	Mencía de Lemus (CAT)		
		Fátima Ventura (CHMP)		
		Elisabeth Rook (COMP)		
		Tim Leest (COMP)		









An Le (HMPC) Jan Taminiau (PDCO) Declan Noone (PRAC) 12:15 Q&A 12:30 Lunch break 3. Medical Devices 13:30 Medical Device Regulation • Expert panels for medical devices: role and function • Patient and HCP potential involvement What are the implications for EMA 14:00 Q&A 4. Clinical Trials 14:30 ACT EU Multitakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Q&A 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism— a new EMA policy 16:30 Wrap up Juan Garcia Burgos 16:40 End of meeting	Time	Topics	Speaker		
Declan Noone (PRAC) 12:15 Q&A 12:30 Lunch break 3. Medical Devices 13:30 Medical Device Regulation • Expert panels for medical devices: role and function • Patient and HCP potential involvement What are the implications for EMA 14:00 Q&A 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars 15:35 Q&A 15:50 Feedback on mini campaigns 6. Multilingualism— a new EMA policy 16:30 Wrap up Juan Garcia Burgos			An Le (HMPC)		
12:35			Jan Taminiau (PDCO)		
12:30 Lunch break 3. Medical Devices 13:30 Medical Device Regulation • Expert panels for medical devices: role and function • Patient and HCP potential involvement What are the implications for EMA 14:00 Q&A 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars EMA's statement on interchangeability of biosimilars 6. Multilingualism— a new EMA policy 16:00 Multilingualism on the EMA website and in external communications— a new policy Juan Garcia Burgos			Declan Noone (PRAC)		
3. Medical Devices 13:30 Medical Device Regulation • Expert panels for medical devices: role and function • Patient and HCP potential involvement What are the implications for EMA 14:00 Q&A 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism— a new EMA policy 16:30 Wrap up Juan Garcia Burgos	12:15	Q&A			
Medical Device Regulation Expert panels for medical devices: role and function Patient and HCP potential involvement What are the implications for EMA 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:30 Wrap up Juan Garcia Burgos	12:30	Lunch break			
Expert panels for medical devices: role and function Patient and HCP potential involvement What are the implications for EMA 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns	3. Medical Devices				
Patient and HCP potential involvement What are the implications for EMA 4. Clinical Trials 4. Clinical Trials 4. CT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars EMA's statement on interchangeability of biosimilars Q&A 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism— a new EMA policy 16:00 Multilingualism on the EMA website and in external communications— a new policy 16:30 Wrap up Juan Garcia Burgos	13:30	Medical Device Regulation	Miguel Antunes (EMA)		
What are the implications for EMA 14:00 Q&A 4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos		Expert panels for medical devices: role and function			
4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars EMA's statement on interchangeability of biosimilars Q&A 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos		Patient and HCP potential involvement			
4. Clinical Trials 14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy Juan Garcia Burgos		What are the implications for EMA			
14:30 ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism- a new EMA policy 16:00 Multilingualism on the EMA website and in external communications - a new policy 16:30 Wrap up Juan Garcia Burgos	14:00	Q&A			
and kick-off meeting 14:45 Q&A 15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos	4. Clinical Trials				
15:00 Coffee break 5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism— a new EMA policy 16:00 Multilingualism on the EMA website and in external communications— a new policy 16:30 Wrap up Juan Garcia Burgos	14:30		Maria Filancia (EMA)		
5. Biosimilars and interchangeability 15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos	14:45	Q&A			
15:15 Update and report from Shortage workshop breakout session EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism- a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos	15:00	Coffee break			
EMA's statement on interchangeability of biosimilars Rosa Gonzalez-Quevedo (EMA) 15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism- a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy Monika Benstetter (EMA) Juan Garcia Burgos	5. Biosimilars and interchangeability				
15:35 Q&A 15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism- a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos	15:15	Update and report from Shortage workshop breakout session	Steffen Thirstrup (EMA)		
15:50 Feedback on mini campaigns Monika Benstetter (EMA) 6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos		EMA's statement on interchangeability of biosimilars			
6. Multilingualism – a new EMA policy 16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Juan Garcia Burgos	15:35	Q&A			
16:00 Multilingualism on the EMA website and in external communications – a new policy 16:30 Wrap up Monika Benstetter (EMA) Juan Garcia Burgos	15:50	Feedback on mini campaigns	Monika Benstetter (EMA)		
communications – a new policy 16:30 Wrap up Juan Garcia Burgos	6. Multilingualism- a new EMA policy				
	16:00	-	Monika Benstetter (EMA)		
16:40 End of meeting	16:30	Wrap up	Juan Garcia Burgos		
	16:40	End of meeting			